“Cost-effective identification of novel pharmacogenetic variants remains a pressing need in the field,” according to Dr. Bertha Hidalgo, assistant professor in the department of epidemiology at the University of Alabama at Birmingham. Therefore, using data from the Genetics Of Lipid Lowering Drugs And Diet Network (GOLDN), Dr. Hidalgo and her team — including UAB department colleague Dr. Stella Aslibekyan, assistant professor; Dr. Howard W. Wiener, statistician; Dr. Ryan Irvin, assistant professor; and Dr. Donna K. Arnett, professor and chair; as well as Dr. Hemant K. Tiwari, professor, in UAB’s department of biostatistics, section on statistical genetics — analyzed statistics from a sample of 173 families to detect genomic regions of importance to fenofibrate response. “Our approach included a multipoint linkage scan, followed by selection of the families showing evidence of linkage.”
The researchers identified a significant signal for changes in LDL-cholesterol (LDL-C) on chromosome 7 (peak logarithm of odds score=4.76) in the complete sample (n=821), which remained after adjusting for baseline LDL-C. In sharing the findings of the study, Dr. Hidalgo writes that “[r]estricting analyses to only the families contributing to the linkage signal for LDL-C (N=19), we observed a peak logarithm of odds score of 5.17 for chromosome 7. Two genes under this peak (ABCB4 and CD36) were of biological interest. These results suggest that linked family analyses might be a useful approach to gene discovery in the presence of a complex (e.g., multigenic) phenotype.”
“A Family-Specific Linkage Analysis of Blood Lipid Response to Fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network” was published in the July issue of Pharmacogenetics and Genomics.